Refine by
Radiopharmaceutical Articles & Analysis
27 news found
Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases. ...
Radiopharm Theranostics Limited (ASX:RAD, RAD or the Company), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the successful completion of the retail component of the fully underwritten 1 for 3.55 prorata accelerated non-renounceable entitlement offer (Entitlement Offer) announced by the ...
bydney, Australia - November n, lull — Kaaiopnarm I neranostics (A:>a:kauj, a aeveioper or a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce agreement with Australia's Nuclear Science and Technology Organisation (ANSTO) to supply the Company with isotope non-carrier-added lutetium-177 (Lu-177) for its ...
Radiopharm Theranostics Limited (ASX:RAD, "RAD" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, refers to its fully underwritten non-renounceable entitlement issue originally announced on 19 October 2022, of 1 New Share for every 3.55 Existing Shares held by Eligible Shareholders at an Offer Price ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM-11 (n.c.a. 177Lu-edotreotide), an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ...
ITM is a supplier of n.c.a. lutetium-177 to health care facilities around the world, and the isotope has been successfully used in various clinical and commercial radiopharmaceutical cancer treatments. “Today we celebrate the efforts of Bruce Power, ITM, our Kinectrics staff, and our partner in Isogen, Framatome, whose collective efforts enabled the start of commercial ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ...
(“FutureChem”) (KOSDAQ: 220100ks), a leading Korean radiopharmaceutical company developing innovative medicines and imaging analysis technology for targeting and treating cancer and neurodegenerative diseases. ...
Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. ...
BySOFIE
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced publication of key results from its Phase 3 SPOTLIGHT trial of F-rhPSMA-7.3 in recurrent prostate cancer in an abstract being presented at the ASCO 2022. ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced a presentation on Axumin® (fluciclovine F 18) at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO), to be held in Orlando, Fla., from December 1 to 3, 2021. ...
BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of David E. Gauden, D.Phil. as its new Chief Executive Officer (CEO). ...
About SENSEI® in thoracic surgery SENSEI® can detect gamma emissions intra-operatively from radiopharmaceuticals. In thoracic surgery, SENSEI® is used to help locate small pulmonary lesions. ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the upcoming oral presentation of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer, at the upcoming ASCO 2022 Genitourinary Cancers Symposium (ASCO GU). ...
Positron has purchased a NeuWise system for delivery in Q1 2022 to validate its performance and capabilities with select radiopharmaceuticals. This validation will be conducted at a Positron customer site and will be in parallel with our FDA application and is the most efficient use of time and resources. ...
CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to develop a nanobody-radionuclide conjugate, currently at preclinical stage. The bioconjugate is based on CIS Pharma’s polymer drug carrier technology and is developed to diagnose and treat B7H3-positive forms of cancer. The target plays a role in the ...
Monitoring the stannous tin (Sn(II)) content in technetium-99m (99mTc) radiopharmaceuticals is essential for quality control. Differential pulse polarography is a straightforward, interference-free, and sensitive technique for this analysis mentioned by the IAEA (International Atomic Energy Agency) Technical Report Series No 466 as analysis method. Metrohm Application Note ...
SENSEI® can detect gamma emissions from radiopharmaceuticals. The first application of the device is sentinel lymph node detection in prostate and cervical cancer surgery. ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of a secondary, post-hoc analysis of data from the prospective LOCATE and FALCON clinical trials that evaluated the impact of Axumin® (fluciclovine F 18) PET/CT imaging on management of patients with recurrent ...